

Impact of New Drugs and Biologics on Colorectal Cancer Treatment and Costs

Pinar Karaca-Mandic, PhD; Jeffrey S. McCullough, PhD; Mustaqeem A. Siddiqui, MBBS; Holly Van Houten, BA; and Nilay D. Shah, PhD

Objective: To compare medical expenditures of patients receiving old and new colorectal cancer (CRC) regimens.

Study Design: Using claims data, we identified 2 cohorts of privately insured patients diagnosed with CRC: first, those diagnosed before new treatment introduction (January 1, 2002, to December 31, 2002), and second, those diagnosed after new treatment introduction (June 1, 2004, to May 31, 2005). CRC diagnosis was identified using *International Classification of Diseases-9* codes 153.xx, 154.xx, and 159.0. First- and second-line chemotherapy regimens were identified. Treatments and expenditures were then observed for up to 2 years after initial diagnosis.

Methods: We estimated multivariate models to measure changes in cost with changes in treatment regimen. Approval dates of new regimens were used as natural experiments.

Results: New regimens, such as fluorouracil, leucovorin, and oxaliplatin (FOLFOX), have rapidly replaced the most prevalent preperiod product (ie, fluorouracil/leucovorin). Changes in treatment have caused large increases in total expenditure, primarily through increases in chemotherapy prices. FOLFOX alone has increased total average cost by 14%. New treatments have not substituted for other medical services; rather, they have indirectly raised costs through nonstandard regimen use and increases in second-line treatment use. We found no evidence that expenditure effects were driven by changes in follow-up duration.

Conclusion: New CRC treatments have increased both regimen choice and expenditures. New regimens have primarily increased expenditures through direct treatment costs; we observed no offsetting expenditure reductions.

(*Am J Manag Care.* 2011;17(5 Spec No.);e160-e168)

For author information and disclosures, see end of text.

Copyright © 2011 by American Society of Clinical Oncology and Managed Care & Healthcare Communications, LLC.

Colorectal cancer (CRC) is the third most frequently diagnosed cancer and the second leading cause of death as a result of cancer in the United States.¹ In 2009, an estimated 147,000 individuals were diagnosed with CRC, and approximately 50,000 died as a result of this condition. However, there have been significant advances in CRC treatment over the past decade. We measured the financial consequences of these innovations.

CRC is usually treated with multiagent regimens. The underlying principle of the combination chemotherapy regimen is that drugs can function through separate mechanisms and may have superior efficacy and effectiveness when administered jointly.² Until recently, 3 regimens dominated the CRC first-line treatment market: fluorouracil (FU), available since the 1960s,³ which has been routinely administered with leucovorin (FU/LV) since the early 1990s⁴ or with irinotecan (IFL or FOLFIRI). The US Food and Drug Administration (FDA) approved 5 new CRC treatments between 1999 and 2004. The most popular regimen combines FU/LV with oxaliplatin (FOLFOX). Use of these drug combinations in metastatic CRC has been found to improve survival.⁵

The FDA also approved new biologic CRC treatments in 2004. These new biologic agents—bevacizumab, cetuximab, and panitumumab—are often referred to as monoclonal antibodies. In effect, these antibodies facilitate immune responses to rapidly proliferating cancer cells. The first agent to be introduced was bevacizumab, which works against the vascular endothelial growth factor and is often used in combination with FOLFOX or FOLFIRI. Cetuximab and panitumumab inhibit the epidermal growth factor receptor, and cetuximab has been tested and used in combination with FOLFIRI. More recent evidence suggests that cetuximab and panitumumab are only effective in patients who have tumors with a KRAS mutation.^{6,7} Table 1 lists common first-line CRC treatment regimens as well as the drugs that make up each regimen and their approval dates.

Although these advances have been welcomed by the oncology community, there has been significant concern about the cost of these treatments.⁸⁻¹⁰ An early editorial after the approval of new CRC treatments showed that the cost of an 8-week course using the Mayo regimen (ie, monthly administration of 5 consecutive days of FU/LV) was \$63.¹¹ This increased to \$11,889 with FOLFOX, \$21,033 with FOLF- OX plus bevacizumab, and \$30,675 with FOLFIRI plus cetuximab. Howard et al¹² recently measured changes in CRC survival and cost

In this issue
Take-Away Points / e161
Published as a Web exclusive
www.ajmc.com

during 2002 to 2005. The authors found that survival increased by 1.4 months, whereas total cost increased by \$4600 among patients with CRC in the Medicare population. Larger increases in survival and spending were observed during the period of 1995 to 2002.

We build on the existing literature by measuring the direct and indirect expenditure effects of new CRC treatment regimens for a privately insured population. Following Howard et al,¹² we used approval dates as a natural experiment to measure the financial consequences of new CRC treatment regimens. These new regimens are associated with substantial increases in total treatment cost. We used a combination of empirical models to decompose this overall change. New regimens generate substantial increases in the direct cost of first-line treatments. We considered 3 potential indirect effects: changes in nonchemotherapy treatment costs, use of nonstandard regimens, and changes in the cost of incumbent products. Nonstandard regimens were defined as a mix of drugs that included typical drugs used in a regimen (eg, FU/LV) as well as other drugs that were not standard in the regimen (eg, FU/LV + capecitabine). Often, additional treatment for nonstandard regimens was initiated weeks to months after the start of the initial treatment regimen. We found no evidence that new regimens change nonchemotherapy medical costs. We did observe small decreases in the cost of older regimens. The rate of nonstandard regimen use increased after the introduction of new treatments; physicians supplemented existing regimens with new products, thus increasing costs. Finally, we considered issues of treatment duration and observed follow-up periods to test and correct for both selection bias and the potential for effective treatments to increase long-run costs through improved survival.

METHODS

Data

We assembled an extensive data set of de-identified pharmacy and medical claims from the IMS Health LifeLink Health Plan Claims Database, provided by IMS Health. The database covers more than 55 million lives and 80 health plans. Data include all claims and encounters, including prescription drugs, inpatient services, outpatient office visits, ambulatory services (such as testing, imaging, and chemotherapy administration), emergency department visits, and home health services. Expenditures reflect total annual payments made by each enrollee (copayments, deductibles, excluded expenses) and by all third-party payers (primary and secondary coverage, net of negotiated discounts).

Take-Away Points

New oncology drugs have rapidly affected both the treatment and the cost of colorectal cancer (CRC). Although new regimens offer the hope of increased survival, they come at a high cost.

- New regimens such as FOLFOX largely substituted for FU/LV and IFL/FOLFIRI.
- New regimens have substantially increased the cost of CRC treatment.
- Increases in FOLFOX-related costs alone account for approximately 14% of total average cost per patient.
- New treatments have not been substitutes for other medical services; rather, they have increased the cost of existing regimens through nonstandard regimen use.

Study Sample

We created 2 distinct cohorts of patients with CRC aged 18 to 64 years: one cohort of those diagnosed before new treatment availability (January 1, 2002, to December 31, 2002) and the other of those diagnosed after new treatment availability (June 1, 2004, to May 31, 2005). We identified CRC diagnoses on the basis of the existence of claims with the *International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM)* for malignant neoplasm of colon, rectum, rectosigmoid junction, anus, or intestinal tract (codes 153.xx, 154.xx, and 159.0). All eligible patients had 1 year of no CRC-related claims preceding their diagnosis.

We identified 12,881 unique patients in the preperiod and 15,416 in the postperiod who had at least 1 claim with the above ICD-9-CM codes. To eliminate any false positives, we also required colorectal claims on 5 or more separate dates within 6 months of the index diagnosis, similar to methods used by Ramsey et al.¹³ The resulting sample included 5597 patients in the preperiod and 6309 in the postperiod. We also required each patient to have received CRC chemotherapy within 6 months of initial diagnosis. Our final analytic data set included 2644 unique patients (10 months average observed follow-up) in the preperiod cohort and 3213 (10.3 months average follow-up) in the postperiod cohort. We ascertained that no preperiod cohort patients were included in postperiod data.

All costs were inflated to 2007 US dollars. Costs were estimated by service type, including inpatient, outpatient, emergency department, laboratory, imaging, and chemotherapy. We also estimated cost across several time dimensions: first, observed cost with up to 1 year of follow-up; second, annualized cost, which is 365 times the ratio of observed cost divided by days of observation; and third, cost during first-line treatment period. Resections were identified using *Current Procedural Terminology-4* procedure codes (44140 to 44160, 44204 to 44212, and 45110 to 45119). Resource utilization was based on claims and included use and costs incurred after initial CRC diagnosis.

CRC Chemotherapy Regimens

We identified CRC chemotherapy drugs using J-codes in

■ **Table 1.** First-Line Regimens and Drug Approval Dates

Regimen	FU	LV	Irinotecan (April 2000)	Capecitabine (May 2001)	Oxaliplatin (January 2004)	Bevacizumab (February 2004)	Cetuximab (February 2004)
FU	•						
FU/LV	•	•					
IFL or FOLFIRI	•		•				
Capecitabine				•			
Capecitabine/irinotecan			•	•			
FOLFOX	•				•		
Capecitabine/oxaliplatin				•	•		
FU/LV + bevacizumab	•	•				•	
IFL + bevacizumab	•		•			•	
Other biologic							•

Date of approval for first-line therapy for advanced/metastatic colorectal cancer.
 FOLFIRI indicates fluorouracil plus irinotecan; FOLFOX, fluorouracil/leucovorin with oxaliplatin; FU, fluorouracil; IFL, fluorouracil plus irinotecan; LV, leucovorin.

the claims. We used combinations of chemotherapy drugs to define chemotherapy regimen based on first chemotherapy treatment after diagnosis. This resulted in 11 exclusive first-line treatment regimens, listed in **Table 1**: FU, FU/LV, IFL or FOLFIRI, capecitabine (an oral FU alternative), capecitabine/irinotecan, FOLFOX, capecitabine/oxaliplatin, FU/LV plus bevacizumab, IFL plus bevacizumab, other biologic, and other.

Only the first 5 regimens were available during the preperiod. The “other biologic” and “other” categories included some regimens that could not be easily classified and that few individuals received. For example, patients receiving FU plus oxaliplatin plus irinotecan or FOLFOX plus irinotecan were classified in the “other” category. Rare regimens that included a biologic, such as capecitabine plus bevacizumab, were categorized in the “other biologic” category. As Table 1 suggests, some of the 11 exclusive categories of first-line treatments are not highly prevalent in our data. Accordingly, we constructed broader first-line therapy regimens by including capecitabine/oxaliplatin and capecitabine/irinotecan in the other category. Similarly, we included FU/LV plus bevacizumab and IFL plus bevacizumab in the “other biologic” category.

Second-line therapy was defined in 2 ways. Typically, chemotherapy regimens for CRC are expected to last 6 months. We observed this to a great extent in the data, but it was not consistent. We defined second-line treatment as the discontinuation of first-line treatment (ie, all agents in the initial regimen) and start of a new treatment regimen 6 to 12 weeks after the end of the initial regimen. We also tested other definitions of switching to second-line treatment, such as discontinuation of initial regimen and start of a new regimen at any time. However, this did not seem to affect the results. Our

method of second-line therapy identification is similar to that used by Kutikova et al.¹⁴

Statistical Analyses

We measured expenditure differences across patients receiving different chemotherapeutic regimens. Naturally, patients receiving more expensive treatment regimens could be costlier for unobserved reasons. This potential selection effect could cause bias in naive models of treatment costs. Consequently, we used FDA approval dates as a natural experiment. In effect, we used patients diagnosed before approval as a control group. Previous studies have used similar identification strategies.^{12,15}

The effects of regimens on expenditures were estimated by generalized linear models (with log link, gamma family). These models included extensive patient-level controls for clinical comorbidities and quarterly indicators for diagnosis dates. These quarterly indicators control for any factors unobserved to the researchers that were common across providers or patients. For example, these variables might capture the effect of unobserved price changes, pharmaceutical marketing efforts, or publication of medical research. Furthermore, we allowed preperiod regimen effects to differ during pre- and postperiods. We estimated the impact of changes in chemotherapy regimen on spending for first-line and non-first-line chemotherapy and on nonchemotherapy spending. We then investigated whether first-line treatments were associated with second-line therapy use (using a logistic model) and with observed length of follow-up time (using a Cox proportional hazard model). Both specifications included the same set of explanatory variables, as discussed.

We conducted a counterfactual exercise to facilitate parameter interpretation. For the postperiod cohort, we assumed that FOLFOX was not available, and patients received either FU/LV (67%) or IFL/FOLFIRI (33%) in proportion to their preperiod distributions. This allowed us to estimate the incremental effect of FOLFOX on cost.

RESULTS

Descriptive Statistics


Table 2 presents descriptive statistics for the preperiod (2644 unique patients) and postperiod (3231 unique patients) cohorts. Average patient age at diagnosis was 56 years in the preperiod cohort and 55 years in the postperiod cohort. Patients in each cohort had approximately 10 months of follow-up. All cost and utilization measures were constructed for 1 year after diagnosis. Total observed cost was substantially higher for the average postcohort patient (\$107,994) relative to the average preperiod patient (\$60,586). This increase was largely driven by increases in inpatient costs (\$26,109 vs \$36,106), chemotherapy administration costs (\$7621 vs \$26,174), and other outpatient costs (\$11,503 vs \$21,713). On average,

■ **Table 2.** Descriptive Statistics for Pre- Versus Postperiod Cohorts

Statistic	Preperiod Cohort (Diagnosed Between January and December 2002)		Postperiod Cohort (Diagnosed Between June 2004 and May 2005)		P
	Mean	SD	Mean	SD	
No. of patients	2644		3231		
Male, %	53.2		53.1		.9783
Age at diagnosis, years	56.0	11.2	54.9	9.9	<.001
Follow-up time, months	10.0	2.9	10.3	2.7	<.001
Costs up to 1 year of follow-up, \$					
Total	60,586	52,385	107,994	85,162	<.001
Inpatient	26,109	38,092	36,106	57,424	<.001
Inpatient/skilled nursing facility	219	2731	120	1586	.0834
Pharmacy	5197	7273	7506	11,910	<.001
Emergency department	199	578	754	4388	<.001
Home health	696	2020	1444	4462	<.001
Office visits	3952	3752	7057	10,131	<.001
Laboratory	892	1080	1185	1353	<.001
X-ray	4199	6269	5933	7436	<.001
Chemotherapy administration	7621	13,761	26,174	34,911	<.001
Other outpatient	11,503	18,901	21,713	28,718	<.001
Utilization^a					
No. of hospital stays	1.4	1.4	1.5	1.4	.0478
Length of hospital stay, days	8.5	7.5	8.1	6.9	.0064
No. of hospital days	12.0	15.5	12.0	15.2	.9305
Comorbid conditions, %					
Myocardial infarction	2.6		2.7		.7723
Congestive heart failure	7.6		8.0		.5765
Peripheral vascular disease	4.2		4.6		.5212
Cerebrovascular disease	4.8		4.9		.9188
Dementia	0.6		1.2		.0225
Chronic pulmonary disease	10.0		12.6		.0017
Ulcer	1.9		2.2		.3526
Mild liver disease	1.0		1.2		.4354
Diabetes	16.5		16.2		.7635
Diabetes with organ damage	2.2		2.0		.5799
Hemiplegia	1.1		0.7		.1539
Moderate/severe renal disease	3.1		3.4		.5569
Moderate/severe liver disease	1.2		1.5		.2992
Metastatic solid tumor	65.3		65.8		.7235
AIDS	0.2		0.3		.4199
Rheumatologic disease	1.0		1.1		.6822
First-line chemotherapy regimen, %					
FU	18.2		23.1		
FU/LV	54.4		24.7		
IFL or FOLFIRI	20.7		7.0		
Capecitabine	6.4		8.8		
Capecitabine/irinotecan	0.1		0.0		
FOLFOX	0.2		32.8		
Capecitabine/oxaliplatin	0.0		0.8		
FU/LV + bevacizumab	0.0		0.4		
IFL + bevacizumab	0.0		0.8		
Other biologic	0.0		1.4		
Other	0.0		0.2		
Second-line therapy, %^b	39.0		42.0		.0028
Resection, %	53.0		64.0		<.001

Data adapted from LifeLink Health Plans Claims Database. FOLFIRI indicates fluorouracil plus irinotecan; FOLFOX, fluorouracil/leucovorin with oxaliplatin; FU, fluorouracil; IFL, fluorouracil plus irinotecan; LV, leucovorin; SD, standard deviation.
^aAll utilization measures represent use during the first year after diagnosis.
^bSecond-line therapy is defined as chemotherapy 6 weeks to 3 months after initial treatment.

■ **Figure.** Share of Each First-line Regimen for (A) Preperiod Cohort (January 1, 2002, to December 31, 2002) and (B) Postperiod Cohort (June 1, 2004, to May 31, 2005)



FOLFIRI indicates fluorouracil plus irinotecan; FOLFOX, fluorouracil/leucovorin with oxaliplatin; FU, fluorouracil; IFL, fluorouracil plus irinotecan; LV, leucovorin.

each cohort had similar numbers of hospital stays (1.4 pre- and 1.5 post-) but pre-period cohort patients had slightly longer hospital stays (8.5 vs 8.1 days). We did not observe any statistically significant differences in prevalence of comorbid conditions across the cohorts, with the exception of dementia and chronic pulmonary disease, which were more prevalent in the postperiod cohort.

Table 2 also lists significant differences in the first-line regimens used by patients in the 2 cohorts. The most popular regimens in the preperiod cohort were FU/LV (54.4%), FU (18.2%), and IFL or FOLFIRI (20.7%). These regimens were still prevalent in the postcohort but not as popular, with only 7% of patients receiving IFL or FOLFIRI and 24.7% receiving FU/LV. Interestingly, the proportion of patients receiving FU increased slightly to 23.1%. The most popular first-line regimen in the postperiod was FOLFOX (32.8%).

Figures A and B present quarterly trends in first-line regimens for the pre- and postperiod cohorts, respectively. Preperiod cohort regimen use was fairly stable over time, but there was a significant decline in FU/LV and IFL or FOLFIRI use during the postperiod. Proportion of patients receiving FU,

another regimen available to the preperiod cohort, remained stable during the postperiod. Figure 1B also demonstrates significant increases in FOLFOX use. FOLFOX use rose from 20.8% in the first quarter of 2004 to 41.9% in the second quarter of 2005. Use of other biologic drugs as first-line regimens also increased from 2% to 6.7% during the same period.

Multivariate Models

Table 3 lists results for a series of cost models. We report results from models of costs incurred only during first-line regimens; however, we found similar results for other cost measures, such as total observed cost up to 1 year of follow-up and total annualized cost (coefficient estimates on regimen indicators were similar across specifications that had these other cost measures as outcome variables). Model 1 examines total cost, model 2 examines cost of chemotherapy agents associated with the regimen only, model 3 examines cost of other chemotherapy agents not directly associated with the first-line regimen, and model 4 focuses on nonchemotherapy costs.

We found that patients using new products incurred higher costs than patients treated with FU or IFL/FOLFIRI. In Table 3, model 1, the parameters for FOLFOX and other biologic were positive (0.23 and 0.31, respectively) and significant ($P < .01$). We used models 2 to 4 to identify mechanisms through which treatment regimen affects spending. In model 2, we found that FOLFOX and other biologics cost 400% more than FU, our reference regimen. Costs associated with our reference category—a generic regimen (ie, FU)—changed little over time, although costs associated with other incumbent products (IFL/FOLFIRI and FU/LV) fell when competing products were introduced.

First-line chemotherapy regimens are frequently supplemented with additional chemotherapy products. Model 3 shows that nonstandard regimen spending did increase for patients receiving IFL/FOLFIRI and FU/LV compared with that for those receiving FU. New products do not directly increase spending on nonstandard regimens. However, they may indirectly increase nonstandard regimen spending when they are used to supplement older regimens.

Finally, model 4 indicates that FOLFOX and other biologics are associated with relatively modest nonchemotherapy expenditure increases. Patients receiving older regimens such as IFL/FOLFIRI and FU/LV incur greater costs than patients receiving FU; however, this effect did not change during the postperiod. Across all specifications, younger patients had higher costs. The prevalence of other comorbidities and resection were also associated with higher total cost (model 1) and nonchemotherapy costs (model 4). As expected, none of the comorbidities had a statistically significant effect on chemotherapy costs (models 2 and 3).

Impact of New Drugs and Biologics on Colorectal Cancer Treatment and Costs

Table 3. Treatment Regimens and Medical Expenditures: Multivariate Models

Characteristic	Generalized Linear Model (log link, gamma family)							
	Model 1		Model 2		Model 3		Model 4	
	Effect	SE	Effect	SE	Effect	SE	Effect	SE
Age	-0.01 ^a	0.001	-0.02 ^a	0.002	-0.01 ^b	0.007	-0.01 ^a	0.001
Female	-0.00	0.020	0.13 ^a	0.045	0.31 ^a	0.118	-0.00	0.023
First-line chemotherapy regimen								
FU (reference)								
IFL/FOLFIRI	0.20 ^a	0.045	4.55 ^a	0.102	-2.13 ^a	0.274	0.18 ^a	0.053
IFL/FOLFIRI × postperiod cohort	0.03	0.071	-0.28 ^b	0.160	2.20 ^a	0.418	0.12	0.083
FU/LV	-0.28 ^a	0.037	2.62 ^a	0.085	-1.24 ^a	0.224	-0.33 ^a	0.044
FU/LV × postperiod cohort	-0.06	0.050	-0.74 ^a	0.114	0.75 ^c	0.303	0.05	0.059
FOLFOX	0.23 ^a	0.035	4.72 ^a	0.079	0.07	0.217	0.09 ^c	0.040
Other ^d	0.26 ^c	0.127	4.93 ^a	0.292	-0.69	0.723	0.11	0.147
Other biologic ^e	0.31 ^a	0.088	4.95 ^a	0.199	0.04	0.511	0.22 ^c	0.102
Capecitabine	-0.15 ^a	0.042	2.92 ^a	0.095	0.04	0.240	-0.06	0.048
Comorbid conditions								
Myocardial infarction	0.07	0.063	0.04	0.141	-0.00	0.376	0.14 ^b	0.073
Congestive heart failure	0.25 ^a	0.039	-0.16 ^b	0.087	-0.34	0.227	0.23 ^a	0.045
Peripheral vascular disease	0.16 ^a	0.049	-0.04	0.110	-0.18	0.298	0.17 ^a	0.057
Cerebrovascular disease	0.15 ^a	0.047	0.07	0.108	-0.14	0.292	0.21 ^a	0.055
Dementia	0.39 ^a	0.105	-0.01	0.235	-0.37	0.584	0.47 ^a	0.124
Chronic pulmonary disease	0.03	0.032	-0.09	0.072	-0.35 ^b	0.188	0.08 ^c	0.037
Ulcer	0.18 ^c	0.070	-0.11	0.159	-0.01	0.410	0.27 ^a	0.081
Mild liver disease	0.25 ^a	0.094	-0.18	0.213	-1.07 ^c	0.540	0.27 ^c	0.109
Diabetes	0.03	0.028	0.01	0.064	0.09	0.166	0.03	0.033
Diabetes with organ damage	0.14 ^b	0.074	0.01	0.165	-0.14	0.433	0.02	0.086
Hemiplegia	0.41 ^a	0.108	-0.13	0.246	-0.73	0.630	0.55 ^a	0.125
Moderate/severe renal disease	0.42 ^a	0.057	-0.16	0.129	0.21	0.322	0.48 ^a	0.066
Moderate/severe liver disease	0.16 [†]	0.087	0.06	0.199	0.63	0.489	0.42 ^a	0.100
AIDS	-0.14	0.184	-0.25	0.417	0.03	1.086	-0.28	0.213
Rheumatologic disease	0.11	0.100	-0.05	0.223	0.04	0.570	0.13	0.118
Resection	0.40 ^a	0.021	0.09 ^b	0.047	-0.41 ^a	0.125	0.19 ^a	0.024
Observations	5874		5873		5873		5873	

All specifications include indicators for quarter of diagnosis. Model 1, total cost during first-line treatment; model 2, first-line chemotherapy treatment agent costs during first-line treatment; model 3, non-first-line chemotherapy costs during first-line treatment; model 4, nonchemotherapy costs during first-line treatment. Data adapted from LifeLink Health Plans Claims Database.
 FOLFIRI indicates fluorouracil plus irinotecan; FOLFOX, fluorouracil/leucovorin with oxaliplatin; FU, fluorouracil; IFL, fluorouracil plus irinotecan; LV, leucovorin.
^aP < .01.
^bP < .1.
^cP < .05.
^dCapecitabine/oxaliplatin and capecitabine/irinotecan are included in "other" category of first-line regimens.
^eFU/LV plus bevacizumab and IFL plus bevacizumab are included in "other biologic" category of first-line regimens.

We also examined the effect of different regimens on the probability of receiving second-line treatment and duration of observed claims data follow-up. Although we observed no differences in follow-up duration (Table 4; model 5), patients receiving newer regimens were more likely to receive second-

line therapies (Table 4; model 6). These analyses are discussed in the Robustness section.

We conducted a counterfactual exercise to help interpret our findings. As Figure 1 suggests, FOLFOX was substituted for FU/LV and IFL/FOLFIRI in the postperiod. Although

■ **Table 4.** Models of Observed Follow-up and Second-Line Treatments

Characteristic	Model 5		Model 6	
	Effect	SE	Effect	SE
Age	-0.00 ^a	0.000	-0.00	0.003
Female	-0.01	0.009	0.09	0.055
First-line chemotherapy regimen, %				
FU (reference)				
IFL/FOLFIRI	-0.04 ^b	0.021	0.44 ^a	0.125
IFL/FOLFIRI × postperiod cohort	-0.01	0.033	0.34 ^c	0.195
FU/LV	0.01	0.017	-0.20 ^c	0.105
FU/LV × postperiod cohort	-0.04 ^c	0.023	0.41 ^a	0.141
FOLFOX	-0.01	0.016	0.30 ^a	0.097
Other ^d	-0.12 ^b	0.058	-0.04	0.358
Other biologic ^e	-0.12 ^a	0.041	0.95 ^a	0.240
Capecitabine	-0.01	0.019	0.08	0.117
Comorbid conditions				
Myocardial infarction	-0.02	0.029	-0.17	0.176
Congestive heart failure	0.03 ^c	0.018	-0.06	0.107
Peripheral vascular disease	0.02	0.022	-0.03	0.136
Cerebrovascular disease	0.01	0.022	0.02	0.132
Dementia	-0.11 ^b	0.048	-0.01	0.291
Chronic pulmonary disease	-0.00	0.014	-0.11	0.088
Ulcer	0.01	0.032	0.21	0.192
Mild liver disease	0.02	0.043	-0.45 ^c	0.272
Diabetes	0.02	0.013	0.12	0.079
Diabetes with organ damage	0.03	0.034	0.27	0.200
Hemiplegia	0.06	0.049	-0.04	0.304
Moderate/severe renal disease	0.01	0.026	-0.08	0.159
Moderate/severe liver disease	-0.02	0.040	-0.09	0.243
AIDS	0.03	0.084	-0.22	0.543
Rheumatologic disease	-0.01	0.045	-0.09	0.280
Resection	0.06 ^a	0.010	0.78 ^a	0.059
Observations	5874		5874	
Second-line therapy is defined as chemotherapy 6 weeks to 3 months after initial treatment. All specifications include indicators for quarter of diagnosis. Model 5, observed follow-up days after diagnosis (Cox proportional hazard model); model 6, probability of second-line treatment (logit). Data adapted from LifeLink Health Plans Claims Database. FOLFIRI indicates fluorouracil plus irinotecan; FOLFOX, fluorouracil/leucovorin with oxaliplatin; FU, fluorouracil; IFL, fluorouracil plus irinotecan; LV, leucovorin. ^a <i>P</i> < .01. ^b <i>P</i> < .05. ^c <i>P</i> < .1. ^d Capecitabine/oxaliplatin and capecitabine/irinotecan are included in “other category” of first-line regimens. ^e FU/LV plus bevacizumab and IFL plus bevacizumab are included in “other biologic” category of first-line regimens.				

approximately 55% of patients received FU/LV and 20% received IFL/FOLFIRI in the preperiod, the shares of these two first-line regimens declined to approximately 15% and 0%, respectively, by the end of the postperiod. At the same time, FOLFOX gained approximately 40% of the market share. We predicted postperiod costs assuming FOLFOX had never been approved. In practice, we limited this analysis to the postperiod and randomly assigned FOLFOX users to either FU/LV or IFL/FOLFIRI proportionately based on their

relative preperiod market shares. We used this random allocation because our multinomial logistic regression model of first-line treatment regimen choices did not identify any patient characteristics influencing treatment choice. We assigned two-thirds of patients receiving FOLFOX in the postperiod to FU/LV and one-third to FU. Using parameter estimates from model 1, we predicted the costs under these older treatment regimens. Mean predicted annual cost for first-line treatment was \$133,617 (standard deviation,

\$44,951) for the postperiod. In the absence of FOLFOX, this cost would have been \$115,204 (standard deviation, \$38,254). FOLFOX directly increased average postperiod chemotherapeutic expenditures by more than \$18,000. This corresponds approximately to a \$15,000 increase in average cost per patient with up to 1 year of follow-up.

Robustness

Our primary empirical concern is that unobserved differences in patient severity (eg, stage at diagnosis) may drive treatment selection. Physicians and patients know more about CRC severity and the appropriateness of a given treatment. If, for example, relatively high severity patients received FOLFOX, we might overestimate the effect of FOLFOX on expenditures. We performed a series of robustness tests to address potential problems such as unobserved severity.

The patterns of preperiod treatment choices described in Figure 1A suggest that the distribution of patient and physician treatment preferences was stable across time in the absence of treatment innovations. This stability provides support for our overall empirical strategy. Howard et al¹² provide additional evidence for the stable distribution of CRC severity across time. We directly tested whether observed measures of patient severity affected treatment choice. We estimated multinomial logistic regression models to predict first-line chemotherapy regimen choices in the pre- and postperiod cohorts. Observable patient characteristics had almost no effect on first-line regimen choice. The exceptions were that older patients were less likely to receive FOLFOX or FOLFIRI, and patients with kidney or liver disease were less likely to receive biologic products. The choice model results were not particularly interesting and were excluded for brevity. These results are available on request from the authors. Although these results suggest that severity did not drive treatment selection, it is possible that selection is only dependent on unobserved patient severity measures.

Our empirical models contain implicit tests for selection bias based on unobserved severity. If the higher cost of FOLFOX were driven by unobserved severity, then the average severity among patients receiving FU/LV and IFL/FOLFIRI would fall during the postperiod. We found that neither observed duration nor nonchemotherapy costs changed during the postperiod. Although first-line chemotherapy costs fell, this was a price rather than quantity effect. The decrease in observed follow-up for patients receiving other biologic products could be the result of selection bias; however, if so, this effect must be small, because we observed no changes in IFL/FOLFIRI or FU/LV follow-up.

The reported empirical and robustness results are all based on expenditures during first-line regimen. Differences in regimen duration might bias these results. Consequently, we es-

timated models based on first-year expenditures and observed expenditures before second-line treatment initiation. In all cases, the results were consistent with those reported. Overall, these results strongly suggest that our findings are robust.

DISCUSSION

This study documents increasing CRC treatment heterogeneity after the introduction of new chemotherapy agents. New regimens, such as FOLFOX, were largely substituted for FU/LV and IFL/FOLFIRI as first-line therapy for metastatic CRC. These treatment changes resulted in large expenditure increases in CRC care. The total average cost during follow-up after diagnosis rose from \$60,586 in the preperiod to \$107,994 in the postperiod. Cost increases from FOLFOX accounted for 14% of the total average postperiod cost. Although the new regimens are costly, there is substantial evidence that these treatments improve survival.¹⁶⁻¹⁹ Our analysis suggests that our price effects are independent of unobserved severity; however, our data are poorly suited to measuring any improved outcomes from new treatments.

We also examined indirect effects on medical costs. The new regimens had no effect on nonchemotherapy medical costs; they did not substitute for other forms of medical expenditure. However, they may have influenced the cost of existing treatment regimens. First, the prices of competing regimens fell during the postperiod, possibly because of competition. Second, the cost of nonstandard regimens rose for patients receiving older regimens as their primary first-line treatment. Third, the probability of receiving second-line therapy increased for nearly all treatments.

Notably, our results are in contrast to those of Howard et al,¹² who performed an analysis of CRC treatment using Medicare data; however, they employed SEER data, which includes stage at diagnosis. Although our populations differed, our sample selection and empirical strategies were quite similar. Howard et al found that new regimens diffused more rapidly and achieved much higher market share.¹² They also found smaller cost effects, with total average expenditure increasing by \$4600 during the analogous period. These differences may be a consequence of unobserved severity differences or federal policy. Differences between Medicare and private insurance reimbursement might also explain this variation in regimen cost and utilization. These differences, along with the 2003 Medicare Prescription Drug, Improvement, and Modernization Act,²⁰ merit further study.

Our report has several limitations. First, our data are not linked to cancer registries. As such, we did not observe stage of cancer at diagnosis, severity of condition, or exact survival. However, we restricted each cohort to newly diagnosed pa-

tients to reduce the heterogeneity of disease severity across individuals. Thus, we are reluctant to assess the clinical effectiveness of existing and new therapies. Furthermore, adverse effects and quality-of-life factors may have influenced discontinuation of therapy. Finally, because this research is based on claims data, it is sensitive to potential diagnosis coding errors.

New oncology drugs have rapidly affected both the treatment and cost of CRC. Although new regimens offer the hope of increased survival, they come at a high cost. Our findings imply that new regimens have been largely substituted for older regimens as first-line therapy for metastatic CRC. These treatment changes have resulted in large expenditure increases for CRC care. New treatments have not been substituted for other medical services; rather, they have increased the cost of existing regimens through nonstandard regimen use. In general, the implications of costly new drugs on rising healthcare spending have been a concern with regard to various therapeutic classes such as antihypertensives, cardiovascular drugs, and specialty drugs for the treatment of rheumatoid arthritis and multiple sclerosis.²¹⁻²⁶ As new clinical research becomes available, there are continuing changes in the treatment and management of cancer that warrant future studies to evaluate the costs and benefits of these new cancer treatments. Moreover, future work must study the impact of pharmacogenomic information (eg, the role of KRAS mutation on success with cetuximab) on the evolution of treatment patterns as oncologists' familiarity with new agents increases.

Acknowledgment

The statements, findings, conclusions, views, and opinions contained and expressed in this article are based in part on data obtained under license from the following IMS Health information service: LifeLink Health Plan Claims Database (data start year to data end year). All rights reserved. The statements, findings, conclusions, views, and opinions contained and expressed herein are not necessarily those of IMS Health or any of its affiliated or subsidiary entities.

Authors' Disclosures of Potential Conflicts of Interest: The authors indicated no potential conflicts of interest.

Author Contributions

Conception and design: Pinar Karaca-Mandic, Jeffrey S. McCullough, Nilay D. Shah. **Financial support:** Nilay D. Shah. **Administrative support:** Nilay D. Shah. **Collection and assembly of data:** Nilay D. Shah. **Data analysis and interpretation:** Pinar Karaca-Mandic, Jeffrey S. McCullough, Holly Van Houten, Nilay D. Shah. **Manuscript writing:** Pinar Karaca-Mandic, Jeffrey S. McCullough, Mustaqeem A. Siddiqui, Holly Van Houten, Nilay D. Shah. **Final approval of manuscript:** Pinar Karaca-Mandic, Jeffrey S. McCullough, Mustaqeem A. Siddiqui, Holly Van Houten, Nilay D. Shah.

Address Correspondence to: Nilay D. Shah, PhD, Division of Health Care Policy and Research, Mayo Clinic, 200 First St SW, Rochester, MN 55905; e-mail: shah.nilay@mayo.edu.

REFERENCES

1. Edwards BK, Ward E, Kohler BA, et al: Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. *Cancer* 116:544-573, 2009

2. DeVita VT, Schein PS: The use of drugs in combination for the treatment of cancer: rationale and results. *N Engl J Med* 288:998, 1973

3. Chu E: Clinical colorectal cancer: ode to 5-fluorouracil. *Clin Colorectal Cancer* 6:609, 2007

4. Erlichman C: Fluorouracil and leucovorin for metastatic colorectal cancer. *J Chemother* 2:38-40, 1990 (suppl 1)

5. Wolpin BM, Mayer RJ: Systemic treatment of colorectal cancer. *Gastroenterology* 134:1296-1310, 2008

6. Amado RG, Wolf M, Peeters M, et al: Wild-Type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. *J Clin Oncol* 26:1626-1634, 2008

7. Karapetis CS, Khambata-Ford S, Jonker DJ, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. *N Engl J Med* 359:1757-1765, 2008

8. Warren JL, Yabroff KR, Meekins A, et al: Evaluation of trends in the cost of initial cancer treatment. *J Natl Cancer Inst* 100:888-897, 2008

9. McFarlane J, Riggins J, Smith TJ: SPIKES: A six-step protocol for delivering bad news about the cost of medical care. *J Clin Oncol* 26:4200-4204, 2008

10. Meropol NJ, Schulman KA: Cost of cancer care: issues and implications. *J Clin Oncol* 25:180-186, 2007

11. Schrag D: The price tag on progress: chemotherapy for colorectal cancer. *N Engl J Med* 351:317-319, 2004

12. Howard DH, Kauh J, Lipscomb J: The value of new chemotherapeutic agents for metastatic colorectal cancer. *Arch Intern Med* 170:537-542, 2010

13. Ramsey SD, Martins RG, Blough DK, et al: Second-line and third-line chemotherapy for lung cancer: use and cost. *Am J Manag Care* 14:297-306, 2008

14. Kutikova L, Bowman L, Chang S, et al: The economic burden of lung cancer and the associated costs of treatment failure in the United States. *Lung Cancer* 50:143-154, 2005

15. Cutler D, McClellan M, Newhouse J, et al: Are medical prices declining? evidence from heart attack treatments. *Q J Econ* 113:991-1024, 1998

16. Lucarelli C, Nicholson S, Song M: Bundling among rivals: a case of pharmaceutical cocktails. <http://www.nber.org/papers/w16321>

17. Giantonio BJ, Catalano PJ, Meropol NJ, et al: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. 025:1539-1544, 2007

18. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. *N Engl J Med* 350:2335-2342, 2004

19. Kabbinnar F, Irl C, Zurlo A, et al: Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk. *Oncology* 75:215-223, 2008

20. Medicare Prescription Drug, Improvement, and Modernization Act of 2003. Pub L 108-173. December 8, 2003

21. Ganguli A, Hong SH: Impact of new antihypertensive drugs on the healthcare utilization of hypertensive patients. *Am J Pharm Benefits* 1:138-144, 2009

22. Joyce GF, Goldman DP, Karaca-Mandic P, et al: Impact of specialty drugs on the use of other medical services. *Am J Manag Care* 14:821-828, 2008

23. Lichtenberg FR: The effect of using newer drugs on admissions of elderly Americans to hospitals and nursing homes: state-level evidence from 1997 to 2003. *Pharmacoeconomics* 24:5-25, 2006 (suppl 3)

24. Lichtenberg FR: The impact of new drugs on US longevity and medical expenditure, 1990-2003: evidence from longitudinal, disease-level data. *Am Econ Rev* 97:438-443, 2007

25. Miller GE, Moeller JF, Stafford RS: New cardiovascular drugs: patterns of use and association with non-drug health expenditures. *Inquiry* 42:397-412, 2005

26. Zhang Y, Soumerai SB: Do newer prescription drugs pay for themselves? a reassessment of the evidence. *Health Aff (Millwood)* 26:880-886, 2007 ■